29 results
8-K
KPRX
Kiora Pharmaceuticals Inc
17 Dec 19
EyeGate Pharma Receives $1.9 Million From Exercised Warrants
8:41am
. The press release also announced that the Company has received the full data package for the study.
The press release is filed as Exhibit 99.1 hereto
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
17 Dec 19
EyeGate Pharma Receives $1.9 Million From Exercised Warrants
8:41am
sufficient cash to fund its planned operations through this evaluation process.
In addition, the Company has received the full data package
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
2 Dec 19
EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study
6:55am
. There were no serious adverse events related to OBG in the study (ocular or non-ocular).
The Company expects to receive the full data package in mid-December
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
22 Nov 19
Other Events
6:55am
by the full data package in mid-December.
“The proven effectiveness and well tolerated safety profile of EyeGate’s OBG eye drop is a major step
8-K
EX-99.1
z4died1
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
FWP
g5pe4dvr
16 Jan 15
Free writing prospectus
12:00am
FWP
600qil 9il
12 Sep 14
Free writing prospectus
12:00am
FWP
l16eu31s 657ahi6ulmf
24 Oct 14
Free writing prospectus
12:00am
FWP
068cv f82egile8q6w
29 Sep 14
Free writing prospectus
12:00am
8-K
EX-10.1
3iu r49yt
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
5z569zq7bgzz oge30
10 Jul 15
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
12:00am